Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week.
Dettori
A G
AG
Centre for Haemostatic Diseases, Ospedale Maggiore, Parma, Italy.
Zamboni
V
V
Manotti
C
C
Canova
N
N
Barbanti
M
M
Palazzini
E
E
D000328:Adult; D001780:Blood Coagulation Tests; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D065427:Factor Xa Inhibitors; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008970:Molecular Weight; D010314:Partial Thromboplastin Time; D012449:Safety; D013918:Thrombin Time
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D003871:Dermatan Sulfate